John Concannon

Harvard University

Papers

1

Total Citations

3

H-Index

1

About

John Concannon is a researcher whose work centers on the development of innovative biochemical assays for drug discovery, with a particular focus on neurodegenerative diseases. His primary research areas include high-throughput screening methodologies, protein misfolding, and the identification of small-molecule inhibitors for conditions like Alzheimer’s and Parkinson’s disease. Concannon’s major contribution lies in the design of a fluorescent quenching-based high-throughput assay to screen for calcineurin inhibitors, a promising therapeutic target for mitigating protein aggregation. Though his most-cited paper, published in 2015, has garnered only 3 citations to date, its conceptual framework addresses a critical gap in treatment options for neurodegenerative disorders linked to protein misfolding. His work underscores the importance of developing scalable, efficient tools to accelerate the discovery of disease-modifying therapies. Concannon’s research exemplifies a targeted approach to tackling complex neurological challenges, offering a foundation for future studies in assay development and drug screening. His efforts contribute to the broader scientific pursuit of effective interventions for devastating conditions that currently lack curative treatments.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Development of a Fluorescent Quenching Based High Throughput Assay to Screen for Calcineurin Inhibitors
3 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Harvard University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago